John Castle,
Executive Director, Vaccine Research and Translational Medicine
We’re defining a new therapeutic paradigm where NGS, bioinformatics, and immunomics are used to generate individualized therapies manufactured on-demand for patients. Originally trained in physics, I moved to Rosetta Inpharmatics, later part of Merck Sharp and Dohme (MSD), where I contributed to the development of novel computational biology, lab and genomic platforms for novel drug targets and biomarkers. In Mainz, Germany, I built a genomics and computational immunology department focused on novel cancer immunotherapies, resulting in first-in-man clinical trials of individualized neoantigen vaccines. At Agenus, we’re pushing the boundaries to rapidly design and manufacture custom-made vaccines for patients and combine the vaccines with immunomodulatory antibodies.
|
|
|
